Photocure fundamentale forhold (PHO)

Savepig · august 9, 2022, 8:06am

Finfint å ha dette på plass til kvartalsrapport!

TekBot · august 10, 2022, 6:02am

Photocure ASA: Results for the second quarter of 2022

Oslo, Norway, 10 August 2022: Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 99.9 million in the second quarter of 2022
(Q1 2021: NOK 88.9 million), and a positive EBITDA of NOK 1.4 million (NOK 5.8
…

Vis børsmeldingen

million). Karl Storz’s new high-definition blue light system is expected to
become commercially available in the United States in late third quarter 2022,
which is in turn expected to accelerate the placement of rigid towers.

“We delivered 12% Hexvix/Cysview revenue growth and 9% unit growth in the second
quarter of 2022, despite delays in the new Karl Storz blue light system launch
and ongoing effects from Covid-19. The commitment of our commercial teams in
both the U.S. and in Europe enabled the business to significantly recover from a
difficult first quarter and achieve positive year over year growth with our base
business, despite the staffing shortages that continue to plague healthcare
systems around the world. While access to care has reopened, many hospital
systems now have stricter rules for non-essential personnel within the facility,
and limited staffing means less time for face-to-face customer engagement.
Nevertheless, in the second quarter of 2022, our U.S. business achieved the
highest unit sales volume in our history, and we continue to increase Cysview’s
penetration into the bladder cancer treatment market,” says Dan Schneider,
President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 100.6 million in the second
quarter of 2022 (NOK 90.4 million), and an EBITDA* of NOK 1.4 million (NOK 5.8
million). The Hexvix/Cysview revenues ended at NOK 99.9 million in the quarter
(Q2 2021: NOK 88.9 million), on higher unit sales in both North American and
Europe and a favorable net benefit from foreign exchange. The EBIT was NOK -4.6
million (NOK -0.2 million) and the cash balance at the end of the second quarter
2022 was NOK 273.1 million. The installed base of blue light cystoscopes in the
U.S. was 329 at the end of the second quarter, an increase of 41 towers or 14%
since the same period in 2021, including a total base of 58 flexible
cystoscopes, which grew 38% year over year.

“I am pleased to reiterate that demand for blue light cystoscopy (BLC[®])
continues to be very strong, and that new high-definition blue light equipment
from Karl Storz is anticipated by our accounts in both the U.S. and European
markets. Major capital equipment suppliers are highly aware of the need, and are
preparing to launch new upgraded blue light systems in Europe. These technology
upgrades are expected to improve the BLC experience for physicians, and we
believe that the use of high-definition towers will further accelerate demand
for Hexvix/Cysview. Our U.S. pipeline for new BLC towers remains robust, and we
continue to work with Karl Storz in preparation of the launch of the new blue
light system later this quarter,” Schneider adds.

With the new Karl Storz system anticipated to launch in the U.S. in late third
quarter of 2022, Photocure expects that the placements of new blue light rigid
towers will accelerate in the fourth quarter of this year. Meanwhile, the
company will continue to focus on increasing the use of Cysview in existing
accounts as well as placing flexible BLC equipment, for which installation
momentum has increased.

“We believe that the second half of this year has potential for some exciting
developments. With healthcare access now reopened and the new high-definition
blue light system expected to launch in the coming weeks, we are looking forward
to significantly expanding the base of blue light capital equipment and
accelerating the growth of our Hexvix/Cysview franchise,” Schneider concludes.

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
second quarter 2022 financial report on page 22.

Photocure will present its second quarter 2022 report on Wednesday 10 August
2022 at 14:00 CEST at Hotel Continental, Oslo, Norway. The investor presentation
will also be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl,
CFO.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20220810_2/

The presentation is scheduled to conclude at 14:45 CEST.

For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +47 45055000
Email: ed@photocure.com

David Moskowitz
Vice-President Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 10 August 2022 at 08:00 CET.

Kilde

E24Bot · august 10, 2022, 6:35am

Resultatreduksjon for Photocure: Ned 4,4 millioner kroner

ufo · august 10, 2022, 10:58am

Veldig godt intervju med DS

TekBot · september 1, 2022, 5:30am

Photocure appoints Anders Neijber, MD, PhD as Chief Medical Officer, Global Medical Affairs and Clinical Development

Press Release - Oslo, Norway, September 1, 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, today announced the appointment of Dr. Anders Neijber to
the position of Chief Medical Officer, Global Medical Affairs and Clinical
…

Vis børsmeldingen

Development and R&D, effective September 1, 2022.

Dr. Neijber is Photocure’s current VP Medical Affairs and Clinical Development
and joined the company in August 2021. He brings over 25 years of substantial
experience in the Uro-oncology area and successful leadership in the
pharmaceutical industry. He has had global and regional leadership roles, both
in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked
for Pfizer, AstraZeneca, Johnson & Johnson, Allergan, Ferring, and Novartis.
[Dr. Anders Neijber]

Dr. Neijber is a board-certified urologist, and has held an Assistant Professor
position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical
School, New Jersey.

“In the time that Anders has been with Photocure, he has proven his ability to
apply his extensive experience and deep knowledge in the field of Urology,
together with his business acumen in leading our Global Medical Affairs
strategy” said Dan Schneider, President and Chief Executive Officer of
Photocure. “As Photocure continues to grow and expand its global reach, Medical
Affairs will have an increasingly important role in navigating the complex
health-care environment. Anders will be able to provide a strategic approach
beyond addressing the heightened regulatory and compliance regulations, to
further build a Global Medical Affairs organization that will have a strong
foundation for future scalability and capability globally.”

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

Tekspert · september 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Savepig (94 likes)

@Rodjer (67 likes)

@myk (40 likes)

Resten av topp 10:

@rosk82 (32 likes)
@Hayen (29 likes)
@kreinh (25 likes)
@Snoeffelen (24 likes)
@Quadruple (20 likes)
@Bingo123 (19 likes)
@Truls2 (11 likes)

Gratulerer!

TekBot · september 8, 2022, 5:32am

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology

Press release - Oslo, Norway, September 8th, 2022: Photocure ASA, The Bladder
Cancer Company, is delighted to continue supporting the global launch activities
of the new and improved Blue Light Cystoscopy (BLC[®]) system to be used with
…

Vis børsmeldingen

Photocure’s product Hexvix[®] for the detection of bladder cancer. In Europe,
the photodynamic diagnostics (PDD) system based on the new light source POWER
LED SAPHIRAT from KARL STORZ was featured for the first time in an E-Masterclass
Webinar, hosted by both companies on September 6. This event was accompanied by
the leading experts in Urology in the field of Bladder Cancer.

Together with the experts from KARL STORZ and Photocure, Prof. Arnulf Stenzl,
Prof. Lukas Lusuardi, Dr. Param Mariappan and Prof. Morgan Rouprêt showcased the
new next-generation Blue Light system to the E-Masterclass participants. Over
400 registered delegates could see how the “IMAGE1 ST SAPHIRA[T]” system
improves visualization of bladder cancer via practical case studies.
Manufactured and commercialized by KARL STORZ, the new Blue Light system is the
next generation, improving the Blue Light experience and providing next-level
visualization.

“In the last months, I have had the opportunity to use the new Saphira light
source, which really ameliorates the quality of the procedure
significantly”, said Prof. Lukas Lusuardi, Professor of the Department of
Urology at Paracelsus Medical University (PMU) Hospital Salzburg, Austria. “The
quality of vision was exceptional - even in white light. With PDD and the new
POWER LED Saphira, I was very comfortable to make the resection and TURBT under
blue light, which was not the case before, I have to say. So especially with the
bipolar resection, I feel quite comfortable to perform the resection under the
blue light, just to be sure in the best possible way”, added Prof. Morgan
Rouprêt, full Professor (academic position) at APHP Sorbonne University, in the
Academic Urology Department of the Pitié-Salpétrière Hospital, in Paris, France.

“We are proud to be part of the ongoing launch of this exciting new high
-definition system in Europe,” commented Dr. Susanne Strauss, Vice President and
General Manager, Europe at Photocure. “Photodynamic diagnostics (PDD) is an
important cornerstone of accurate diagnosis and treatment of bladder cancer.
This advancement in KARL STORZ’s equipment will provide a better Blue Light
experience for our customers, as the overwhelmingly positive feedback from the e
-masterclass clearly shows,” Susanne Strauss concluded.

“PDD started in Germany, with the full commitment of KARL STORZ, and so it is a
pleasure for us to introduce the new IMAGE1 ST SAPHIRAT system in the E
-Masterclass on NMIBC with PDD,” said Paolo Cantù, Director Urology Global
Marketing at KARL STORZ. “The new light source POWER LED SAPHIRA[T] will allow
us to serve the needs of our healthcare partners, providing high image quality
in white light as well as in blue light for the detection and treatment of
bladder cancer. Together with the Photocure team we now make high-quality BLC
available to more patients worldwide”.

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.
SaphiraT is a registered trademark of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

About KARL STORZ
The medical technology company KARL STORZ was founded in 1945 in Tuttlingen,
Germany, and is an international leader in the world of endoscopy. Now in its
third generation, the family-owned company employs 8,300 people in 40 countries
worldwide. The company portfolio includes more than 15,000 products for human
and veterinary medicine. KARL STORZ stands for visionary design, precision
craftsmanship and clinical effectiveness. Sales for the fiscal year 2021
amounted to 1.97 billion euros. Production sites are located in Germany, the
USA, Switzerland and Estonia. Please find more information at: www.karlstorz.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

TekBot · september 15, 2022, 7:36am

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Press release - Oslo, Norway, September 15, 2022: Photocure ASA (PHO: OSE), The
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) has communicated today on the inclusion of Hexvix[®] in the 2022 edition
…

Vis børsmeldingen

of the Lecheng Global Specialty Drug Insurance Specialty Drug List.

As a new specialty drug benefit plan developed under the guidance of the
government covering 40 domestic specialty drugs and 60 overseas specialty drugs,
the Lecheng Global Specialty Drug Insurance allows Hainan citizens access to
more advanced medical resources and comprehensive coverage of their medical
needs.

In December 2021, Hexvix received initial clinical use in the Boao Lecheng
International Medical Tourism Pilot Zone in Hainan Province when the first
prescription in China was issued at Hainan General Hospital, and the first
patient procedure was completed. Asieris received approval from the National
Medical Products Administration (NMPA) for Hexvix to be included in phase III
clinical trials in the first quarter of 2022 as well as a real-world clinical
data pilot study.

Asieris expects the incorporation of Hexvix into the Lecheng Global Specialty
Drug Insurance to help them explore innovative access models, so that innovative
drugs can be introduced into China and covered by commercial insurance earlier
and faster.

Read Asieris’ full media release here: Hexvix®, A Diagnostic Drug of Asieris, is
Now Covered by the 2022 Lecheng Global Specialty Drug Insurance - Asieris
Pharmaceuticals (https://asieris.com/hexvix-a-diagnostic-drug-of-asieris-is-now
-covered-by-the-2022-lecheng-global-specialty-drug-insurance/)

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Isreal. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

TekBot · september 20, 2022, 5:30am

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

Press release - Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder
Cancer Company, announces the publication of first results from the Laser III
clinical study in the medical journal, European Urology. The study is part of a
…

Vis børsmeldingen

systematic program aimed at verifying the safe treatment of bladder tumors in
the outpatient setting. Laser III results demonstrate the non-inferiority of
outpatient laser-mediated destruction of bladder tumors in conjunction with blue
light cystoscopy (BLC[®]) and Hexvix[®] versus inpatient BLC TURBT* under
general anesthesia. Photocure has supported this program and the specific study
since 2016.

Laser III is a prospective, randomized, non-inferiority trial conducted in the
Capital Region of Denmark from 2016 to 2020 (NCT02886026). Patients with
histologically verified Ta low-grade bladder tumor recurrence were enrolled. A
total of 206 patients were randomized; 176 finished treatment and were available
for follow-up as per protocol. The first results, now published in European
Urology, evaluated 4-month non-inferiority of outpatient laser-mediated ablation
of recurrent Ta tumors with flexible cystoscopes under local anesthesia,
compared to TURBT under general anesthesia. Both the out-patient laser procedure
and TURBT procedure were performed under BLC-guidance. Four-month recurrence
-free survival was assessed as the primary endpoint with a predefined non
-inferiority criterion of 15%. Secondary outcome measures were pain during the
outpatient laser ablation, postoperative morbidity, postoperative complications,
and patient’s preference. The 12-month follow-up results are expected to be
presented in a second paper.
Four-month recurrence-free survival was 8% higher after laser-ablation of the
bladder tumor compared to TURBT, and the predefined noninferiority criterion was
met. The study authors conclude that laser intervention in the outpatient
setting is as good as TURBT with general anesthesia, and has less complications.

In addition, the paper also advocates the importance of enhanced cystoscopy to
mediate this practice change. As recommended by the guidelines, enhanced
cystoscopy should be used during surgical treatment of non-muscle invasive
bladder cancer to improve detection and reduce recurrence.

“The study outcomes clearly demonstrate that for patients with small low grade
stage Ta bladder tumors the procedure can be safely moved from the OR to the
office, thereby reducing the burden for patients stemming from general
anesthesia and cost related to hospital stays. Safety is the most important term
here. Our team find that blue light cystoscopy with Hexvix in the OPD support
the identification of small bladder tumors which therefore safely can be removed
with laser before they become too large for outpatient treatment.” said Dr.
Gregers G Hermann, the Lead Investigator of this study and Consultant Urologist,
MD, DM Sc, F.E.B.U., Dept. of Urology, Herlev/Gentofte hospital, Denmark.

“We expect to see more scientific studies investigating how some of the more
intensive procedures like TURBTs can be reduced, avoided, or made more bearable
for patients. In non-muscle-invasive bladder cancer especially, where most
patients are over 55 years old, research into reducing patient burden is of
great importance. We believe BLC with Hexvix/Cysview can help responsible
researchers in these efforts by minimizing the concern of uncertainty when it
comes to detecting the tumors,” said Dan Schneider, President and CEO of
Photocure.

Read the full publication here:
Outpatient Photodynamic Diagnosis–guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis–guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial - ScienceDirect

(Clinicaltrials.gov Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors - Full Text View - ClinicalTrials.gov)

*TURBT: Transurethral resection of bladder tumor

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

CanonBoy · september 20, 2022, 6:36am

Denne var veldig positiv for flex og fremtidig bruk og utbredelse av systemet. Å behandle pasienter uten innleggelse på sykehus og ekstra bedøvelse vil være mye mer effektivt og kostnadsbesparende. Det må selvsagt gjennomføres flere studier, men dette lover godt for FBLC og utbredelse til mindre klinikker.

“The study outcomes clearly demonstrate that for patients with small low grade
stage Ta bladder tumors the procedure can be safely moved from the OR to the
office, thereby reducing the burden for patients stemming from general
anesthesia and cost related to hospital stays. Safety is the most important term
here. Our team find that blue light cystoscopy with Hexvix in the OPD support
the identification of small bladder tumors which therefore safely can be removed
with laser before they become too large for outpatient treatment.” said Dr.
Gregers G Hermann"

“Four-month recurrence-free survival was 8% higher after laser-ablation of the
bladder tumor compared to TURBT, and the predefined noninferiority criterion was
met. The study authors conclude that laser intervention in the outpatient
setting is as good as TURBT with general anesthesia, and has less complications.”

TekBot · september 26, 2022, 6:20am

Photocure ASA – Major shareholding disclosure

TekBot · september 28, 2022, 5:30am

Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

Karl Storz and Photocure to collaborate on commercializing the high-definition
system

…

Vis børsmeldingen

Press Release - Oslo, Norway, September 28, 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces the commercial availability of Karl Storz’s
New Blue Light equipment powered by SaphiraT in the U.S. As part of the rollout,
Karl Storz plans to host a Virtual Launch event for the medical community
streamed from its El Segundo, California office where Sia Daneshmand M.D. and
Kristin Scarpato M.D. M.P.H. will discuss the clinical benefits of using BLC[®]
with Cysview[® ]for NBMIC*, while sharing their perspectives on the advantages
that the New Blue Light system provides over the original system for TURBT**.
The Virtual Launch event is scheduled to take place on October 13, 2022 at
4:00pm Pacific Time.

“We are pleased to share that Karl Storz has begun filling Obsolescence
Protection Program (OPP) orders for customers who purchased New Blue Light
system upgrades last year,” said Geoff Coy, Vice President and General Manager,
North America. “Orders for the new Saphira system appear to be outpacing orders
from the past signaling pent up demand for the advanced technology, and we
expect to begin filling new account orders in the fourth quarter. Given the
strong demand, we continue to believe that BLC is on its way to becoming the
standard of care for endoscopic visualization of bladder cancer.”

“Uro-oncologists and their staff have expressed a strong desire to have the new
Blue Light system at their hospitals, and the upcoming Virtual Launch Event is
an opportunity to showcase the system’s benefits and broaden awareness of BLC in
the market,” said Ken Pugh, Head of North America Marketing and Alliance
Management. “Accordingly, we are working diligently with our partners to ensure
that all customers who want The New Blue Light, have it for all appropriate
patients with NMIBC.”

Dr. Sia Daneshmand, M.D., is Professor of Urology with Clinical Scholar
designation and serves as director of clinical research as well as the urologic
oncology (SUO) fellowship director at the University of Southern California
(USC) in Los Angeles.
Dr. Kristin Scarpato, M.D., M.P.H., is Associate Professor Department of Urology
residency program director and vice chair of education for the Department of
Urology, Division of Urologic Oncology at Vanderbilt University Medical Center
in Tennessee.

*NMIBC: Non-muscle invasive bladder cancer

**TURBT: Transurethral resection of bladder tumor

Note to editors:

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.
IMAGE1 ST and SaphiraT are registered trademarks of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022]
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

Tekspert · oktober 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Savepig (101 likes)

@Rodjer (64 likes)

@myk (61 likes)

Resten av topp 10:

@rosk82 (57 likes)
@Hayen (44 likes)
@Snoeffelen (38 likes)
@kreinh (26 likes)
@Bingo123 (23 likes)
@Quadruple (22 likes)
@nordpolen (20 likes)

Gratulerer!

GrevenAvGral · oktober 10, 2022, 1:06pm

@TekBot må på jobb, børsmelding på SEB over 5%

TekBot · oktober 25, 2022, 6:45am

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Oslo, Norway, 25 October 2022: Photocure ASA (Photocure, PHO: OSE) will announce
the third quarter 2022 financial results on Wednesday 2 November 2022 at 08:00
CEST and will present a live webcast at 14:00 CEST the same day.
…

Vis børsmeldingen

The quarterly report and presentation will be published at 08:00 CEST and will
be publicly available at www.photocure.com.

The investor presentation will be streamed live and be hosted by Daniel
Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and
questions can be submitted throughout the event. The presentation is scheduled
to conclude at 14:45 CEST.

The streaming event is available through
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221102_7.

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · november 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (91 likes)

@Savepig (90 likes)

@rosk82 (64 likes)

Resten av topp 10:

@myk (57 likes)
@Hayen (55 likes)
@Snoeffelen (50 likes)
@Quadruple (21 likes)
@solskimm (21 likes)
@nordpolen (20 likes)
@Bingo123 (20 likes)

Gratulerer!

TekBot · november 2, 2022, 7:01am

Photocure ASA: Results for the third quarter of 2022

Oslo, Norway, 2 November 2022: Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 96.9 million in the third quarter of 2022,
up 12% compared to Q3 2021 (NOK 86.7 million), and positive EBITDA of NOK 4.7
…

Vis børsmeldingen

million (NOK -0.2 million) for the Company. With the launch of Karl Storz’s new
high-definition blue light system in the U.S., Photocure expects that placements
of new blue light rigid towers will begin to accelerate in the fourth quarter of
this year. A recent ruling by the Centers for Medicare and Medicaid Services
(CMS) improves U.S. reimbursement for Cysview, expanding access in the
Ambulatory Surgery Center (ASC) segment.

“Photocure delivered Hexvix/Cysview revenue growth of 12%, driven by higher unit
sales in both North America and Europe in addition to the net favorable effect
of foreign exchange. I am very pleased to report that our North American
business segment achieved the highest quarterly unit sales volume in our
history, and we are now in a strong position to significantly expand the
installed base of blue light capital equipment in the U.S. and get back to the
high growth trajectory that we were achieving before the pandemic,” says Daniel
Schneider, President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 106.8 million in the third
quarter of 2022 (NOK 87.4 million), and EBITDA* of NOK 4.7 million (NOK -0.2
million), driven by the increase in product revenue and a milestone payment from
Asieris. Hexvix/Cysview revenues ended at NOK 96.9 million in the quarter (Q3
2021: NOK 86.7 million), due to higher unit sales in both North America and
Europe, and net favorable foreign exchange. EBIT was NOK -1.4 million (-6.3
million) and the cash balance at the end of Q3 2022 was NOK 283.9 million.

Photocure announced the commercial availability of Karl Storz’s new high
-definition blue light rigid system in the United States late in the quarter.
The Company reports that 10 new blue light towers were installed during the
period; 6 new SaphiraT cystoscopes and 4 flexible units. The installed base of
blue light cystoscopes in the U.S. was 339 (302) at the end of the third
quarter, a 12% increase from the same period last year. This includes 62
flexible cystoscopes, an increase of 38%.

“The pipeline for new blue light cystoscopy towers remains stronger than ever.
With the new system now officially launched, we are currently assisting Karl
Storz with the placement and activation of towers for accounts that participated
in the obsolescence protection program to replace the old standard definition
system. We anticipate broader installations of rigid BLC equipment in new
accounts this quarter,” Schneider adds.

With the launch of Karl Storz’s new high-definition blue light system in the
U.S. at the end of the third quarter 2022, Photocure expects that placements of
new blue light rigid towers will accelerate in the fourth quarter of this year
and beyond. Additionally, the post-period ruling by CMS to improve Medicare
reimbursement is anticipated to help increase sales in the Hospital-Based
Outpatient Department (HOPD) setting and enable Photocure’s U.S. commercial team
to penetrate accounts in the ASC site of care.

“With account access now open in our major markets, Karl Storz’s new blue light
system launching, and an improvement in Medicare access and reimbursement
expected to take effect January 1 of next year, I believe that Photocure’s
business is at an inflection point. We remain focused on positioning the
Hexvix/Cysview franchise as the standard of care in the management of bladder
cancer,” Schneider concludes.

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
third quarter 2022 financial report on page 22.

The quarterly report and presentation will be published at 08:00 CET and will be
publicly available at www.photocure.com. Daniel Schneider, CEO and Erik Dahl,
CFO, will host a live webcast at 14:00 CET.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221102_7

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 2 November 2022 at 08:00 CET.

Kilde

TekBot · november 3, 2022, 1:54pm

Major shareholder disclosure in Photocure ASA

Bingo123 · november 3, 2022, 2:12pm

SEB solgte seg litt ned?

myk · november 3, 2022, 2:32pm

Ja ser det men skjønner det ikke for SEB til sammen har mye mer enn 5%. Det må være en konto som er redusert til 4,99%.